Skip to main content
Top
Published in: Osteoporosis International 12/2008

01-12-2008 | Letter

Calculating clinically relevant drug doses to use in animal studies

Authors: R. K. Fuchs, M. R. Allen, K. W. Condon, S. Reinwald, L. M. Miller, D. McClenathan, B. Keck, R. J. Phipps, D. B. Burr

Published in: Osteoporosis International | Issue 12/2008

Login to get access

Excerpt

Dear Editor, …
Literature
1.
go back to reference Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB (2008) Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19:1331–1341 doi:10.1007/s00198-008-0602-6 PubMedCrossRef Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB (2008) Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19:1331–1341 doi:10.​1007/​s00198-008-0602-6 PubMedCrossRef
2.
go back to reference Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822PubMedCrossRef Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822PubMedCrossRef
3.
go back to reference Seeman E (2006) Strontium ranelate: vertebral and non-vertebral fracture risk reduction. Curr Opin Rheumatol 18(Suppl 1):S17–S20PubMedCrossRef Seeman E (2006) Strontium ranelate: vertebral and non-vertebral fracture risk reduction. Curr Opin Rheumatol 18(Suppl 1):S17–S20PubMedCrossRef
4.
go back to reference Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468PubMedCrossRef Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468PubMedCrossRef
5.
go back to reference Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21(4):536–542PubMedCrossRef Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21(4):536–542PubMedCrossRef
6.
go back to reference Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104(10):1363–1374PubMedCrossRef Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104(10):1363–1374PubMedCrossRef
7.
go back to reference Borchrd R, Barbes C, Eltherington L (1992) Drug dosage in laboratory animals. CRC, Boca Raton, p 514 Borchrd R, Barbes C, Eltherington L (1992) Drug dosage in laboratory animals. CRC, Boca Raton, p 514
8.
go back to reference Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y (1993) An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8(5):607–615PubMedCrossRef Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y (1993) An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8(5):607–615PubMedCrossRef
9.
go back to reference Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87(5):2060–2066PubMedCrossRef Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87(5):2060–2066PubMedCrossRef
Metadata
Title
Calculating clinically relevant drug doses to use in animal studies
Authors
R. K. Fuchs
M. R. Allen
K. W. Condon
S. Reinwald
L. M. Miller
D. McClenathan
B. Keck
R. J. Phipps
D. B. Burr
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 12/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0741-9

Other articles of this Issue 12/2008

Osteoporosis International 12/2008 Go to the issue